In 2016, AMCP made pre-approval information exchange (PIE) a legislative priority recognizing its vital importance to patients. On June 8, 2022, the U.S. House of Representatives passed the PIE Act of 2022. Learn more about PIE as a legislative priority for AMCP.
AMCP Format 4.1 includes new sections describing the evidence needs of HCDMs for unapproved products nearing the end of the product development pipeline, as well as unapproved uses of existing products for which FDA approval is being sought.
June 2022 Legislative & Regulatory Briefing; ICYMI: Come (Learn) PIE with Me eLearning Days Webinar; AMCP Joins Pharmacy Stakeholders Advocating for PHEPharmacy Staffing Flexibility; [Blog] Why PIE and the Prescription Digital TherapeuticsAct Matter: Recap of AMCP Legislative Days.
May 2022 Legislative & Regulatory Briefing; ICYMI: AMCP Policy & Government Relations Agenda Webinar; AMCP Officially Named Healthy People 2030 Champion; ICYMI: Come (Learn) PIE with Me eLearning Days Webinar.
March 2022 Legislative & Regulatory Briefing; AMCP Legislative Agenda 2022 and Beyond Webinar –Thursday, April 7; AMCP Signals Support for Legislative Priorities; AMCP Supports Authorization for Pharmacists to OrderCOVID-19 Antivirals; AMCP Responds to Part D Proposed Rule; AMCP is a Healthy People 2030 Champion.
